This past week was a bit of mixed bag for earnings for pharmaceutical companies, with giant Pfizer beating estimates as a large efficacy study starting with up to 30,000 participants for its coronavirus vaccine.
Lilly had mixed results, while Sanofi beat earnings estimates.
Biotech/healthcare-oriented hedge funds historically have been a mixed bag too. In 2019, many of these sector hedge funds reported large double-digit gains and some stumbled in the first half of 2020. And now as the global health emergency continues to ramp up, this return dispersion seems to be . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.
